Mesoblast (Mesoblast) Market Cap

: $551.12 Mil (As of Today)

View and export this data going back to 2006. Start your Free Trial

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mesoblast's share price for the quarter that ended in Dec. 2023 was $0.1667. Mesoblast's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 1,014.80 Mil. Therefore, Mesoblast's market cap for the quarter that ended in Dec. 2023 was $169.17 Mil.

Mesoblast's quarterly market cap declined from Jun. 2023 ($714.85 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($169.17 Mil).

Mesoblast's annual market cap declined from Jun. 2021 ($1,038.70 Mil) to Jun. 2022 ($329.02 Mil) but then increased from Jun. 2022 ($329.02 Mil) to Jun. 2023 ($714.85 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mesoblast's Enterprise Value for Today is $610.67 Mil.

Mesoblast Market Cap Historical Data

The historical data trend for Mesoblast's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Market Cap

485.65

1,255.00

1,038.70

329.02

714.85

Mesoblast Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap																446.62	574.02	714.85	-	169.17

Competitive Comparison

For the Biotechnology subindustry, Mesoblast's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast Market Cap Distribution

For the Biotechnology industry and Healthcare sector, Mesoblast's Market Cap distribution charts can be found below:

* The bar in red indicates where Mesoblast's Market Cap falls into.

Mesoblast Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Mesoblast's Market Cap for the fiscal year that ended in Jun. 2023 is calculated as

Market Cap (A: Jun. 2023 )	=	Share Price (A: Jun. 2023 )	*	Shares Outstanding (EOP) (A: Jun. 2023 )
	=	$0.833	*	858.159
	=	$714.85

Mesoblast's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$0.1667	*	1014.8
	=	$169.17

Mesoblast (OTCPK:MEOBF) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Mesoblast Market Cap Related Terms

Thank you for viewing the detailed overview of Mesoblast's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

MESO:USA LWB:Germany MSB:Australia

Address

Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.